英文_EFPIA_制药行业数据概览_26页_3mb

报告摘要

Medical Advancements: (cid:49)(cid:53)(cid:46)(cid:56) + Clinical Trials → 12-13 years + development time for new drugs; average cost per new chemical/biological entity: €3.13B (2022). Groundbreaking therapies (e.g., cell/gene treatments) are expanding treatment options for complex diseases.
Health Benefits: Europe’s population expects ~30 years longer life due to pharmaceutical innovations addressing major causes of death (e.g., HIV/AIDS, cancers).

R&D Investment: €55B (2024) + high employment (~950,000 direct, indirect 3x more). Europe is #3 globally in pharmaceutical innovation, behind US and China.
Trade Balance: Dominant role in high-technology exports, with ~38.2% of EU’s trade surplus. Top partners: US, UK (38.3%), Switzerland (32.6%), France, and Germany (16.4%).
Employment: Pharma industry is a major employer (940k+, 3x indirect jobs), with over 70% in R&D, supporting skilled roles and preventing brain drain.

Global Market: US remains largest revenue source (54.8% of 2024 sales), but China is rising in innovation (#1 in new drug origins in 2024). European sales share ~22.7%.
Parallel Trade: Estimated €6.5B (2023) disrupts supply and funding, undermining market integrity.
Pricing & VAT: Retail price breakdown: Distributors/State ~1/3; significant variations in VAT rates (e.g., France: 20% standard rate for prescription drugs).
Sales Trends: Generic/biosimilar uptake varies by region; generics dominate markets in Central/Eastern Europe. Veterinary/pharmacy sales are separate from human healthcare indicators.

Cost/Risk: High R&D costs (€3.13B/year) with low success rates (1/10,000 substances to market). Challenges include regulatory hurdles, rising costs, and fiscal pressures.
Geopolitical Shifts: Competition from China + fragmentation of EU markets pushing R&D towards the US. China surpassed Europe/US in 2024 for first-time drug launches.
Emerging Economies: Rapid growth in Brazil, India + China attracts research/market shifts from Europe.

Healthcare expenditure averages 9% of GDP in Europe, with pharma (~17.4%) being the smallest component; savings from new drugs reduce broader healthcare costs.

Despite regulatory and cost pressures, pharma remains critical for medical and economic progress. Future success relies on research cooperation, navigating geopolitical shifts, and addressing market fragmentation within Europe.

展开完整摘要